Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Optune Pax® in Combination With Chemotherapy for Locally Advanced Pancreatic Cancer
02/11/2026
Janelle Bradley
The FDA has approved Optune Pax® in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer based on phase 3 PANOVA-3 results showing a statistically significant improvement in overall survival and...
The FDA has approved Optune Pax® in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer based on phase 3 PANOVA-3 results showing a statistically significant improvement in overall survival and...
The FDA has approved Optune Pax®...
02/11/2026
Oncology
Dory Abelman, PhD, HBHSc
Conference Coverage
Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma
02/11/2026
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc,...
02/11/2026
Oncology
Janice J Huang and Alex Reznik
Videos
Identifying Systemic Barriers to Clinical Trial Completion in Head and Neck Cancer
02/11/2026
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346...
02/11/2026
Oncology
Donna Catamero, ANP-BC, OCN, CCRC
Conference Coverage
Exploring the Rapidly Evolving Landscape of Targeted Therapy for Multiple Myeloma
02/11/2026
Donna Catamero, ANP-BC, OCN, CCRC
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN,...
02/11/2026
Oncology Learning Network APP Institute
From Oncology Learning Network APP Institute
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
Campbell Roxburgh, MD
Videos
Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer
02/10/2026
Campbell Roxburgh, MD
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses...
02/10/2026
Oncology
Conference Coverage
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical...
02/09/2026
Oncology

Videos

Dory Abelman, PhD, HBHSc
Conference Coverage
Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma
02/11/2026
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc,...
02/11/2026
Oncology
Janice J Huang and Alex Reznik
Videos
Identifying Systemic Barriers to Clinical Trial Completion in Head and Neck Cancer
02/11/2026
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346...
02/11/2026
Oncology
Donna Catamero, ANP-BC, OCN, CCRC
Conference Coverage
Exploring the Rapidly Evolving Landscape of Targeted Therapy for Multiple Myeloma
02/11/2026
Donna Catamero, ANP-BC, OCN, CCRC
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN,...
02/11/2026
Oncology Learning Network APP Institute
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
Campbell Roxburgh, MD
Videos
Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer
02/10/2026
Campbell Roxburgh, MD
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses...
02/10/2026
Oncology
Mustafa Basree, DO
Conference Coverage
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute
Lucian Zhao, MD
Conference Coverage
Stereotactic Ablative Radiotherapy Delays Systemic Therapy Escalation in Oligoprogressive Renal Cell Carcinoma
02/06/2026
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses...
02/06/2026
Oncology
Luciano Costa, MD
Videos
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
Conference Coverage
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical...
02/09/2026
Oncology
Conference Coverage
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor
02/06/2026
Stephanie Holland
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase...
02/06/2026
Oncology
News
LDH and α-HBDH as Prognostic Biomarkers in Extensive-Stage Small Cell Lung Cancer
02/06/2026
Emily Estrada
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early...
02/06/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use